How long does it take for Revumenib-Revuforj to develop drug resistance?

Revumenib (Revumenib)-Revuforj is a new type of small molecule targeted drug, mainly used for patients with relapsed or refractory acute leukemia (including AML, ALL) carrying lysine methyltransferase 2A gene (KMT2A) translocation. As a precision targeted therapy drug, Revuforj blocks the abnormal proliferation and survival signals of leukemia cells by inhibiting the interaction between KMT2A fusion protein and its downstream transcription factors, thereby achieving the purpose of fighting leukemia.

However, as with most targeted drugs, drug resistance is a problem that must be paid attention to in clinical use. Leukemia cells have a high degree of genetic heterogeneity and the ability to proliferate rapidly. When exposed to a single targeted inhibitor for a long time, they may gradually become desensitized to the drug through mechanisms such as gene mutation, pathway activation, or drug efflux. This means thatRevuforj may experience reduced efficacy or disease recurrence in some patients, but the resistance time varies significantly due to individual differences and is closely related to the patient's genetic background, disease burden, drug dosage, and combination treatment regimen.

Clinical data shows that in the early stage of treatment, the vast majority of patients can significantly reduce the proportion of leukemia cells. However, when the treatment course lasts for several months or even more than half a year, some patients may develop resistance at the molecular level. Scientists are delaying or overcoming drug resistance through combination therapy, dose optimization, and the development of second-generation targeted drugs. For example, combining Revuforj with chemotherapy drugs or other targeted inhibitors is expected to prolong the development of drug resistance while maintaining efficacy.

In addition, patients should receive regular molecular monitoring and bone marrow assessment during treatment to detect resistance signals early. Once disease progression or resistance at the molecular level occurs, the treatment plan can be adjusted according to the guidance of the doctor, such as changing targeted drugs, adding combination regimens, or considering hematopoietic stem cell transplantation.

Reference materials:https://www.drugs.com/monograph/revumenib.html